tbuckley/cabot-search huggingface dataset:
A phase 2 randomized, double-blind, placebo-controlled trial of radium-223 dichloride with exemestane and everolimus in patients with HER2–negative hormone receptor–positive breast cancer and bone metastases.
Authors: Hope S. Rugo, Rui Li, Oana Petrenciuc, Amily Zhang, Robert E. Coleman
Journal: Journal of Clinical Oncology (2016)

TPS621 Background: Treatment options for bone-dominant metastatic breast cancer (MBC) are limited.Radium-223 (Ra-223), a first-in-class α emitter with a targeted antitumor effect on bone metastases (mets), was well tolerated and reduced bone biomarker levels in a phase 2 study in patients with bone-dominant MBC (Coleman et al. Breast Cancer Res Treat 2014). In patients with HER2- estrogen receptor+ (ER+) bone-dominant MBC, everolimus + exemestane (EVE+EXE) improved progression-free survival (PFS) vs EXE alone. Ra-223 plus EVE+EXE may improve outcomes in patients with HER2- ER+ bone-dominant MBC; this trial will evaluate efficacy and safety of Ra-223 vs placebo in these patients (NCT02258451). Methods: Eligible patients are pre- or postmenopausal with HER2- ER+ MBC and ≥ 2 bone or soft tissue mets. Patients must have measurable disease per RECIST v1.1, ≥ 1 prior line of hormone therapy for MBC, and 1-2 prior skeletal-related events; be on bisphosphonates or denosumab; and have an ECOG score of 0-1. Patients must have had no past or current need for chemotherapy for MBC, no unresolved spinal cord compression, and no prior EVE treatment. Patients are randomized to receive (1:1) Ra-223 (50 kBq/kg IV) or placebo × 6 cycles q 4 wk plus EXE (25 mg PO q d) + EVE (10 mg PO q d) plus best supportive care. EXE+EVE continues until disease progression or unacceptable toxicity. Stratification is by geographic region (EU/N Amer v Asia), prior hormone therapy (1 v ≥ 2), and presence of visceral disease (yes v no). Safety and efficacy are assessed every 4 weeks. Long-term safety is assessed until study termination.The primary end point is symptomatic skeletal event (SSE)–free survival. Secondary end points are overall survival; times to opiate use, pain progression, and chemotherapy; radiologic PFS; and safety. Assuming a 1-sided α of 0.1, 90% power, ~ 160 SSEs will be required for the analysis. Efficacy will be analyzed by a stratified log-rank test. Safety analysis will be descriptive. Estimated enrollment is ~ 311 patients. Currently, 29 patients are randomized. Clinical trial information: NCT02258451.
Systemic inflammation response index (SIRI): A prognostic factor in pancreatic cancer (PC)
Authors: Vilma Pacheco Barcia, Rebeca Mondéjar Solís, Olga Donnay Candil, Jacobo Rogado Revuelta, de la Maza López Olmedo Maria Dolores Fenor, Ramon Colomer Bosch
Journal: Annals of Oncology (2017)
Randomized phase III study of fluoropyrimidine (FP) plus bevacizumab (BEV) vs. FP plus irinotecan (IRI) and BEV as first-line therapy for metastatic colorectal cancer (mCRC): German AIO KRK0110 (ML22011)- study.
Authors: Dominik Modest, von Weikersthal Ludwig Fischer, Thomas Decker, Ursula Vehling-Kaiser, Jens Uhlig, Michael Schenk, Jens Freiberg-Richter, Bettina Peuser, Claudio Denzlinger, Christina Peveling genannt Reddemann, Ullrich Graeven, Gunter Schuch, Ingo Schwaner, Arndt Stahler, Andreas Jung, Swantje Held, Sebastian Stintzing, Clemens Giessen-Jung, Volker Heinemann
Journal: Annals of Oncology (2017)
LONG TERM OUTCOME OF IMPLANTABLE CARDIOVERTER DEFIBRILLATORS IN ADULTS WITH CONGENITAL HEART DISEASE
Authors: Zeliha Koyak, Bart A. Mulder, Isabelle C. van Gelder, Joris R. de Groot, Marcelle D. Smit, Pascal F.H.M. van Dessel, Alexander H. Maass, Arthur A.M Wilde, Petronella G. Pieper, Reinoud E. Knops, Barbara J.M. Mulder
Journal: Journal of the American College of Cardiology (2010)
Ruxolitinib during Peritransplant Period for Myelofibrosis Patients Undergoing Allogeneic Stem Cell Transplantation Reduces Acute Graft-Versus-Host Disease
Authors: Nicolaus Kröger, Sharifah Shahnaz Syed Abd Kadir, Tatjana Zabelina, Christine Wolschke, Francis A. Ayuk, Anita Badbaran, Maximilian Christopeit
Journal: Blood (2016)
Gastric cancer in young patients: Prognostics factors and therapeutic results
Authors: Mariem Benhami, Hajar Ouahbi, Layla El Achhab, Lamia Amaadour, Zineb Benbrahim, Fatemazahra El M'rabet, Samia Arifi, Nawfal Mellas
Journal: Annals of Oncology (2017)
Abstract 17353: Cerebral Vasoreactivity is Limited in Single-ventricle Children With High Baseline Cerebral Blood Flow
Authors: Peter J Schwab, David R Busch, Madeline E Winters, Kobina Mensah-Brown, Erin M Buckley, Jennifer M Lynch, Mary E Putt, Tiffany S Ko, Lisa M Montenegro, Susan C Nicolson, Thomas L Spray, J W Gaynor, Stephanie Fuller, Arastoo Vossough, Daniel J Licht, Mark A Fogel
Journal: Circulation (2016)

Background: Depressed cerebral CO2 reactivity (CO2R) is a measure of stressed vascular reserve and is associated with hypoxic-ischemic neurological injury in pediatric patients. Hypothesis: Differe...
Comparative outcomes of cefazolin versus nafcillin for methicillin-susceptible Staphylococcus aureus bacteraemia: a prospective multicentre cohort study in Korea
Authors: S. Lee, K.-H. Song, S.-I. Jung, W.B. Park, S.H. Lee, Y.-S. Kim, Y.G. Kwak, Y.K. Kim, S.M. Kiem, H.-I. Kim, E.S. Kim, K.-H. Park, N.J. Kim, H.-C. Jang, H.B. Kim, S.-M. Choi, K.U. Park, C.J. Kim, J.E. Cho, Y.J. Choi, J. In Park, T.S. Kim, P.G. Choe, W.B. Park, N.-H. Kim, M.J. Lee, S.J. Choi, J.H. Jeon, D.-K. Kim, S.-A. Song, M.J. Kang, J.G. Shin, J. Yi, S. Park, H.K. Choi, M.S. Han, C.R. Cho, H.S. Song, Y.S. Lee, S.-J. Kang, H.-J. Hwang, S. Cheon, J.H. Hwang, S.J. Yun, K.T. Kwon, S.M. Shin
Journal: Clinical Microbiology and Infection (2017)
Epigenetic silencing of CDKN2A, p14(ARF) and CDKN2B and TRβI in head and neck cancers.
Authors: Jonathan Clavell, Raul Bernabe, Adriana Baez
Journal: Cancer Research (2008)

4299   The aim of this study was to determine the association between methylation status of multiple tumor suppressor genes, p16(INK4A), p14(ARF), p15 (INK4B) in a HNSCCs and clinicopathological parameters. Aberrant methylation of p16(INK4A), is common gene silencing mechanism in HNSCC. However, aberrant methylation of p15 (INK4B) appears to be important and recently we demonstrated that TRβI is silencing by aberrant methylation. We investigated CpG island methylation of p16(INK4A), p14(ARF), p15 (INK4B) in a series of 55 primary HNSCCs and on healthy tissue to assess specificity of aberrant methylation. The samples were tested by methylation specific PCR (MSP) while gene expression was detected with real time RT-PC. Of the 55 HNSCCs examined, 34 (62%) tumors showed aberrant methylation at least on one of the genes tested and 15 % had two genes hypermethylated and 5% had three genes hypermethylated. Methylation frequencies varied with p16(INK4A) the most methylated and p14(ARF) the least. Aberrantly methylated genes were detected at early states (I and II) and at late stages (III and IV). No association between p16 (INK4A), p14 (ARF). p15 (INK4B) methylation and conventional clinicopathological parameters was observed. The presence of p14 (ARF) methylation was associated with shorter patient survival. In summary, we have identified a set of aberrant methylation signatures of the 9p21 locus tumor suppressor genes CDKN2A/p14(ARF)/CDKN2B that may be useful as tumor markers for the early identification of HNSCC patients.
Prevalence of Thyroid Autoantibodies and Thyroid Dysfunction in an Inflammatory Bowel Disease Population
Authors: M Hamed, G McCormack
Journal: Endoscopy (2006)

Introduction: The increased incidence of autoimmune diseases in an inflammatory bowel disease (IBD) population is well recognised. The presence of thyroid specific autoantibodies and thyroid dysfunction is reported to be higher in IBD patients.
Cytokine mediators of chronic graft-versus-host disease
Authors: Kelli P.A. MacDonald, Bruce R. Blazar, Geoffrey R. Hill
Journal: Journal of Clinical Investigation (2017)

Substantial preclinical and clinical research into chronic graft-versus-host disease (cGVHD) has come to fruition in the last five years, generating a clear understanding of a complex cytokine-driven cellular network. cGVHD is mediated by naive T cells differentiating within IL-17–secreting T cell and follicular Th cell paradigms to generate IL-21 and IL-17A, which drive pathogenic germinal center (GC) B cell reactions and monocyte-macrophage differentiation, respectively. cGVHD pathogenesis includes thymic damage, impaired antigen presentation, and a failure in IL-2–dependent Treg homeostasis. Pathogenic GC B cell and macrophage reactions culminate in antibody formation and TGF-β secretion, respectively, leading to fibrosis. This new understanding permits the design of rational cytokine and intracellular signaling pathway–targeted therapeutics, reviewed herein.
Treatment Outcomes in Patients Treated with Tyrosine Kinase Inhibitors in "Slovak Registry of Chronic Myeloid Leukemia" (CAMELIA SK)
Authors: Zuzana Sninska, Martin Mistrik, Katarina Slezakova, Ludmila Demitrovicova, Eva Mikuskova, Imrich Markuljak, Juraj Chudej, Natalia Stecova, Elena Tothova, Adriana Kafkova, Stanislav Palasthy, Jana Lesko-Andrascikova, Tereza Necasova, Eva Koritakova
Journal: Blood (2016)
Lymphopenia association with planning target volume and lung V5 and its effect on survival of esophageal cancer receiving neoadjuvant chemo-radiation with Dutch CROSS regime
Authors: Him So Tsz, K.O. Lam, D.L.W. Kwong, S.Y.K. Law, T.W. Leung, H.C.W. Choi, D.K.H. Tong, V.H.F. Lee, S.Y. Chan, W.L. Chan, B.T.T. Law
Journal: Annals of Oncology (2017)
Using clinical data to define a prognostic model for patients with stage I or II colon carcinoma
Authors: Luis Onate-Ocana, Sagrario González-Trejo, Doris Carmona-Herrera, Jose Carrillo, Roberto Herrera-Goepfert, Francisco Ochoa-Carrillo, Vincenzo Aiello-Crocifoglio, Dolores Gallardo-Rincon
Journal: Annals of Oncology (2017)
Randomized phase II study of cetuximab vs. irinotecan and cetuximab in patients with chemo-refractory KRAS codon G13D metastatic colorectal cancer (G13D-study): Compared with ICECREAM study
Authors: Keiichiro Ishibashi, Masato Nakamura, Akihito Tsuji, Yasutaka Takinishi, Yoshiaki Shindo, Toru Aoyama, Junichi Sakamoto, Koji Oba, Hideyuki Mishima
Journal: Annals of Oncology (2017)
Abstract 128: Patches Of Atrial Appendage Tissue Improve Ventricular Function After Myocardial Infarction
Authors: Jun Luo, Matthew S Weaver, Kristina G Bernardi, James E Dennis, Margaret D Allen
Journal: Circulation Research (2013)

Introduction: Atrial appendage (AA) is an expendable autologous tissue source containing cardiomyocytes, inherent cardiac progenitors, and endothelial cells. We hypothesize that AA tissue can be employed as a unique hormonally-active external patch for infarct repair and that inducing the cytoprotective factor, heme oxygenase-1 (HO-1), would enhance survival in transplanted patch cardiomyocytes. Methods: AA patches (5x7mm) were transplanted from donor F344 rats onto hearts in isogenic recipients immediately after acute myocardial infarction (MI). Recipient rats were randomized to receive acute MI only, or external AA patches from donors pretreated with PBS or with the HO-1 inducer, cobalt protoporphyrin (CoPP), 5mg/kg, 24 hrs prior to AA harvest (n=9/group). Echocardiography was performed at baseline and at 4 wks, at which point hearts were excised and fixed for image analysis. Results: At 4 wks post-MI, % fractional shortening was 41% higher (P &lt; 0.01) in HO-1-induced and 32% higher (P = 0.03) in PBS-treated AA patch implant groups vs. MI-only controls. In atrial patches, HO-1 induction significantly reduced collagen deposition compared to PBS-pretreated patches (10 ± 3% vs. 16 ± 5% of ventricular area, P &lt; 0.05), increased atrial cardiomyocyte-containing graft area by 35% (Fig. 1), and preserved connexin 43 expression in atrial grafts. Conclusions: External implantation of cardiomyocyte patches derived from AA tissue increased ventricular function after acute MI. Preemptive induction of pro-survival factor HO-1 showed additional advantages in preserving cardiomyocyte mass and gap junctions, and reducing fibrosis in transplanted cardiomyocyte patches.
Are you ready for “collaborative health”?
Authors: Fiona Godlee
Journal: BMJ (2017)

“A reform is a correction of abuses; a revolution is a transfer of power.” So said the Victorian essayist Edward Bulwer-Lytton. Patient centred care began as a correction of abuses, says our essayist Michael Millenson (doi:10.1136/bmj.j3048), a response to patients being treated like “imbeciles and inventory.” It is now a mix of partnership and paternalism, he says, and the real transfer of power is yet to come. He calls this result “collaborative health” and says it will shape 21st century medicine. So we’d better …
Genomic alterations (GA) and tumor mutational burden (TMB) in large cell neuroendocrine carcinoma of lung (L-LCNEC) as compared to small cell lung carcinoma (SCLC) as assessed via comprehensive genomic profiling (CGP).
Authors: Young Kwang Chae, Keerthi Tamragouri, Jon Chung, Alexa Betzig Schrock, Bhaskar Kolla, Shridar Ganesan, James Suh, Vamsidhar Velcheti, Trever Grant Bivona, Jeffrey S. Ross, Phil Stephens, Vincent A. Miller, Manish Patel, Francis J. Giles, Siraj Mahamed Ali, Sai-Hong Ignatius Ou, Victoria Wang
Journal: Journal of Clinical Oncology (2017)

8517 Background: SCLC and L-LCNEC are aggressive neoplasms that are both associated with smoking history and are thought to overlap in clinical, histogenetic, and genomic features. We reviewed the genomic profiles of &gt;1187 patients to assess the genomic similarities of these diseases. Methods: Comprehensive genomic profiling (CGP) of tumors from 300 L-LCNEC and 887 SCLC patients in the course of clinical care was performed to suggest pathways to benefit from therapy. Results: Commonly altered genes in both diseases included TP53, RB1, MYC/MYCL1, MLL2, LRP1B and PTEN; alterations in other genes occurred at somewhat differing frequencies (table). For both diseases, RB1 mutation significantly co-occurred with TP53 mutations (p&lt;0.001), but occurred in a mutually exclusive fashion to STK11 and CDKN2A (p&lt;0.001). RB1 was mutually exclusive with KRAS for L-LCNEC but not for SCLC. The interquartile range for SCLC and L-LCNEC TMB is 7.9 and 12.6 with the 75% quartile being 14.4 and 17.1 respectively. Cases of both diseases will be presented with radiographic response to genomically matched targeted therapy and immunotherapy, particularly in cases of high TMB. Conclusions: Given the similar overall genomic profiles and clinical behavior of a subset of these diseases, they could be conceived of as a single disease to be further classified by genomically defined classes such as SCLC-type ( TP53/ RB1mutated) and NSCLC-like (wild type for one or both). By analogy to NSLC and melanoma, benefit from immunotherapy appears most likely for only the upper quartile of cases in TMB. [Table: see text]
Natural history and outcomes of synchronous and metachronous colorectal cancers (CRC): A population-based analysis.
Authors: Jackson Chu, Ozge Goktepe, Winson Y. Cheung
Journal: Journal of Clinical Oncology (2013)

3593 Background: Early data suggest that synchronous and metachronous CRC portend a worse prognosis when compared to solitary CRC. Our aims were to 1) characterize the clinical features and treatment patterns of synchronous and metachronous CRC and 2) compare their survival outcomes with those of solitary CRC. Methods: All patients diagnosed with non-metastatic CRC between 1999 and 2008 and referred to any 1 of 5 regional cancer centers in British Columbia, Canada were reviewed. Synchronous and metachronous CRC were defined as multiple (2 or more) distinct tumors that were diagnosed within and beyond 6 months of the date of index CRC diagnosis, respectively, during the study period. Patients with liver metastases at initial diagnosis were excluded. Kaplan-Meier and Cox regression analyses were used to estimate survival among the different CRC groups. Results: A total of 6360 patients were identified: 6147 (96%) solitary, 178 (3%) synchronous and 35 (1%) metachronous tumors; median age was 68 years (IQR 59-76); 57% were men; and 75% were ECOG 0/1 at the time of index cancer diagnosis. Baseline demographic characteristics were comparable across patients (all p&gt;0.05). Compared with solitary CRC, synchronous and metachronous CRC more commonly affected the colon rather than the rectum (84 vs 85 vs 59%, respectively, p&lt;0.001), but presenting symptoms, treatment approaches, and use of chemotherapy, radiation and surgery were similar among the different tumor groups (all p&gt;0.05). In terms of survival, no differences were observed in 3-year relapse free survival (66 vs 66 vs 56%, p=0.20), 5-year cancer specific survival (69 vs 69 vs 53%, p=0.34) and 5-year overall survival (62 vs 59 vs 49%, p=0.74) for solitary, synchronous and metachronous CRC, respectively. These findings persisted after controlling for known prognostic factors, such as age and ECOG. Conclusions: In this large population-based cohort, there were no differences in survival outcomes among solitary, synchronous and metachronous CRC. Patients who present with multiple tumors in the colon or the rectum should be managed similarly to those who present with an isolated tumor.
Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy
Authors: Michael A. Cannarile, Martin Weisser, Wolfgang Jacob, Anna-Maria Jegg, Carola H. Ries, Dominik Rüttinger
Journal: Journal for ImmunoTherapy of Cancer (2017)

The tumor-permissive and immunosuppressive characteristics of tumor-associated macrophages (TAM) have fueled interest in therapeutically targeting these cells. In this context, the colony-stimulating factor 1 (CSF1)/colony-stimulating factor 1 receptor (CSF1R) axis has gained the most attention, and various approaches targeting either the ligands or the receptor are currently in clinical development. Emerging data on the tolerability of CSF1/CSF1R-targeting agents suggest a favorable safety profile, making them attractive combination partners for both standard treatment modalities and immunotherapeutic agents. The specificity of these agents and their potent blocking activity has been substantiated by impressive response rates in diffuse-type tenosynovial giant cell tumors, a benign connective tissue disorder driven by CSF1 in an autocrine fashion. In the malignant disease setting, data on the clinical activity of immunotherapy combinations with CSF1/CSF1R-targeting agents are pending. As our knowledge of macrophage biology expands, it becomes apparent that the complex phenotypic and functional properties of macrophages are heavily influenced by a continuum of survival, differentiation, recruitment, and polarization signals within their specific tissue environment. Thus, the role of macrophages in regulating tumorigenesis and the impact of depleting and/or reprogramming TAM as therapeutic approaches for cancer patients may vary greatly depending on organ-specific characteristics of these cells. We review the currently available clinical safety and efficacy data with CSF1/CSF1R-targeting agents and provide a comprehensive overview of ongoing clinical studies. Furthermore, we discuss the local tissue macrophage and tumor-type specificities and their potential impact on CSF1/CSF1R-targeting treatment strategies for the future.
Radiotherapy in patients with HIV: current issues and review of the literature
Authors: Filippo Alongi, Niccolò Giaj-Levra, Savino Sciascia, Alessandra Fozza, Sergio Fersino, Alba Fiorentino, Rosario Mazzola, Francesco Ricchetti, Michela Buglione, Dora Buonfrate, Dario Roccatello, Umberto Ricardi, Zeno Bisoffi
Journal: The Lancet Oncology (2017)
Mammography use, incidence, and survival of primary breast lymphoma.
Authors: Humnah Khudayar, Jaleh Fallah, Roy Souaid, Adam J. Olszewski
Journal: Journal of Clinical Oncology (2017)

e13087 Background: Breast lymphoma is rare and, unlike in carcinoma, surgery is not the primary treatment modality, so early detection may not contribute to survival. Caon et al. ( Clin Breast Cancer 2012) reported that 85% of aggressive lymphomas are diagnosed by a palpable mass, while 56% of indolent subtypes, by mammography. Our objective was to compare incidence, clinical features, and survival of breast lymphomas according to prevalence of screening mammography. Methods: From the United States SEER registry, we selected primary breast lymphomas diagnosed in 2000-2013 among women ≥40 years old, distinguishing DLBCL, marginal zone (MZL), follicular (FL), and other histologies. Mammography use in county of residence was expressed as % of women ≥40 years old with a mammogram in past 2 years, estimated from the National Cancer Institute’s small-area models. We calculated incidence rates (IR) for each county, and compared them in a Poisson model (with 95% confidence intervals, CI). Head and neck (H&amp;N) lymphomas were used as sensitivity controls. Overall survival (OS, from diagnosis) was compared in a Cox model adjusting for age, race, and median income in the county. Results: We identified 1662 cases of breast lymphoma, with a median age of 69 years. The most common subtypes were DLBCL (39%), MZL (26%), and FL (16%). Stage distribution was: 1 in 62%, 2 in 17%, and 3 or 4 in 21%. Incidence of breast lymphoma increased by 24% for every 10% increase in mammography use (IR ratio, 1.24, 95%CI, 1.15-1.34, P&lt;.0001). This relationship was absent for controls with H&amp;N lymphoma (IR ratio, 1.02, 95%CI 0.97-1.07, P=.43). In breast lymphoma, there was no difference in histologies ( P=.19), stage ( P=.83), or OS by mammography prevalence (hazard ratio 1.01 for every 10% increase, 95%CI, 0.87-1.18, P=.87). OS at 5 years was 60% for DLBCL, 77% for MZL, and 84% for FL. Conclusions: Prevalent mammography use is associated with increased incidence of breast lymphoma, without evident change in stage distribution or survival. Further research will be needed to investigate responsible causal pathways, or potential overdiagnosis. [Table: see text]
Results of randomized phase II trial of dabrafenib versus dabrafenib plus trametinib in BRAF-mutated papillary thyroid carcinoma.
Authors: Manisha H. Shah, Lai Wei, Lori J. Wirth, Gregory A. Daniels, Jonas A. De Souza, Cynthia Dawn Timmers, Jennifer L. Sexton, Mamdouh Beshara, Debra Nichols, Norka Snyder, Catherine E Devine, Bhavana Konda, Naifa Lamki Busaidy
Journal: Journal of Clinical Oncology (2017)

6022 Background: BRAF mutations are present in ~44% of papillary thyroid carcinoma (PTC) and its role in development of PTC is well established. We hypothesized that dabrafenib (BRAF inhibitor) would have efficacy in BRAF mutated PTC and that combining it with trametinib (MEK inhibitor) would result in greater clinical efficacy than dabrafenib alone, through vertical inhibition of the RAF/MAP/ERK pathway and mitigation of potential mechanisms of resistance. Methods: Patients (pts) with BRAF mutated radioiodine refractory PTC who had evidence of disease progression within 13 months prior were randomized to Arm A (dabrafenib 150 mg PO BID) or Arm B (dabrafenib 150 mg PO BID + trametinib 2 mg PO qd). Cross-over to Arm B was allowed at time of progression. Responses were assessed by modified RECISTv1.1 every 2 months. Primary endpoint was objective response rate (ORR) (complete-, partial- and minor-response). With assumed true ORR of 15% vs 35%; and 90% power to identify the correct regimen as most promising, 26 pts were to be accrued in each Arm. Results: In this randomized phase 2 trial, 53 pts (median age 63 years, 38 females) were enrolled; 25% of pts had 1-3 prior therapy with multi-kinase inhibitors. Median follow up was 13 months. Preliminary efficacy results are outlined in Table. The treatment-related adverse events were similar to previously reported phase III clinical trial of these drugs in melanoma. Conclusions: Single agent dabrafenib, as well as combination of dabrafenib/trametinib are well tolerated therapies that result in similar high objective response rates with durable responses in pts with progressive BRAF-mutated PTC. BRAF-pathway targeted therapies provide novel treatment options. Clinical trial information: NCT01723202. [Table: see text]